{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:22:24Z","timestamp":1779916944601,"version":"3.53.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.radonc.2018.02.022","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T01:05:19Z","timestamp":1520730319000},"page":"310-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy"],"prefix":"10.1016","volume":"127","author":[{"given":"Prashant","family":"Gabani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ansstas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner M.","family":"Johanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2018.02.022_b0005","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Melanoma of the Skin. [cited 2017 June 24, 2017]; Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"10.1016\/j.radonc.2018.02.022_b0010","first-page":"572","article-title":"Survival rates of patients with metastatic malignant melanoma","volume":"7","author":"Sandru","year":"2014","journal-title":"J Med Life"},{"key":"10.1016\/j.radonc.2018.02.022_b0015","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.02.022_b0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0025","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.02.022_b0030","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.02.022_b0035","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.radonc.2018.02.022_b0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","article-title":"Immune resistance orchestrated by the tumor microenvironment","volume":"213","author":"Gajewski","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.radonc.2018.02.022_b0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/86297","article-title":"A fresh look at tumor immunosurveillance and immunotherapy","volume":"2","author":"Smyth","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.radonc.2018.02.022_b0050","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.soc.2017.01.007","article-title":"Novel opportunities to use radiation therapy with immune checkpoint inhibitors for melanoma management","volume":"26","author":"Ahmed","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.radonc.2018.02.022_b0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","article-title":"An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer","volume":"1","author":"Golden","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2018.02.022_b0060","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.02.022_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2016.06.003","article-title":"Radiotherapy and immune checkpoints inhibitors for advanced melanoma","volume":"120","author":"Filippi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0070","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0075","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0360-3016(86)90378-0","article-title":"The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study","volume":"12","author":"Overgaard","year":"1986","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.022_b0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.radonc.2018.02.022_b0085","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.radonc.2018.02.022_b0090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.radonc.2018.02.022_b0095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jpainsymman.2004.08.008","article-title":"Pain and palliative care: the emergence of new specialties","volume":"29","author":"Seymour","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.radonc.2018.02.022_b0100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0360-3016(81)90007-9","article-title":"The results of different fractionation schemes in the palliative irradiation of metastatic melanoma","volume":"7","author":"Katz","year":"1981","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.022_b0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1097-0142(19880115)61:2<243::AID-CNCR2820610207>3.0.CO;2-K","article-title":"Analysis of dose fractionation in the palliation of metastases from malignant melanoma","volume":"61","author":"Konefal","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.02.022_b0110","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2010.11.026","article-title":"Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline","volume":"79","author":"Lutz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.022_b0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2018.02.022_b0120","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0125","doi-asserted-by":"crossref","first-page":"20170257","DOI":"10.1259\/bjr.20170257","article-title":"Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma","volume":"90","author":"Franceschini","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2018.02.022_b0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1748-717X-7-164","article-title":"A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases","volume":"7","author":"Fumagalli","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacr.2017.02.040","article-title":"Adoption of radiation technology among privately insured nonelderly patients with cancer in the United States, 2008 to 2014: a claims-based analysis","volume":"14","author":"Pan","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.radonc.2018.02.022_b0140","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1259\/0007-1285-46-543-220","article-title":"Abscopal effect of radiation in papillary adenocarcinoma","volume":"46","author":"Ehlers","year":"1973","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2018.02.022_b0145","doi-asserted-by":"crossref","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2018.02.022_b0150","doi-asserted-by":"crossref","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2018.02.022_b0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","article-title":"Safety and efficacy of radiation therapy in advanced melanoma patients treated with Ipilimumab","volume":"96","author":"Qin","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.022_b0160","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/2326-6066.CIR-15-0156","article-title":"Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma","volume":"4","author":"Theurich","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2018.02.022_b0165","unstructured":"National Comprehensive Cancer Network. Melanoma (Version I.2017). 2017 [cited 2017 June 24, 2017]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/melanoma.pdf."},{"key":"10.1016\/j.radonc.2018.02.022_b0170","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2013.08.035","article-title":"Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes","volume":"88","author":"Barker","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.02.022_b0175","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.critrevonc.2017.01.017","article-title":"The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership","volume":"111","author":"Chajon","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2018.02.022_b0180","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/1078-0432.CCR-16-0870","article-title":"Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma","volume":"23","author":"Kalbasi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2018.02.022_b0190","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.02.070","article-title":"Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice","volume":"150","author":"Seifert","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.radonc.2018.02.022_b0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/path.1700640403","article-title":"The sensitivity of lymphocytes to ionising radiation","volume":"64","author":"Trowell","year":"1952","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.radonc.2018.02.022_b0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fonc.2012.00191","article-title":"Radiation-induced effects and the immune system in cancer","volume":"2","author":"Kaur","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.10098","article-title":"Analysis of radiation-induced apoptosis in human lymphocytes: flow cytometry using Annexin V and propidium iodide versus the neutral comet assay","volume":"48","author":"Wilkins","year":"2002","journal-title":"Cytometry"},{"key":"10.1016\/j.radonc.2018.02.022_b0210","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0215","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.4049\/jimmunol.173.4.2462","article-title":"Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells","volume":"173","author":"Liao","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2018.02.022_b0220","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2018.02.022_b0225","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1158\/1078-0432.CCR-07-4462","article-title":"T-cell responses to survivin in cancer patients undergoing radiation therapy","volume":"14","author":"Schaue","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2018.02.022_b0230","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2018.02.022_b0235","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1471-2407-8-360","article-title":"The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines","volume":"8","author":"Deacon","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2018.02.022_b0240","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/cbr.2011.0973","article-title":"Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines","volume":"26","author":"Dillman","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.radonc.2018.02.022_b0245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1084\/jem.171.1.249","article-title":"Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action","volume":"171","author":"Cameron","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.radonc.2018.02.022_b0250","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003649","article-title":"Phase 1 study of stereotactic body radiotherapy and interleukin-2\u2013tumor and immunological responses","volume":"4","author":"Seung","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.radonc.2018.02.022_b0255","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018301142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018301142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T05:59:10Z","timestamp":1531375150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814018301142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0167814018301142"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2018.02.022","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2018.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}